Alyteserin-2a [S7K]

General Information


DCTPep ID  DCTPep02089

Peptide Name   Alyteserin-2a [S7K]

Sequence  ILGKLLKTAAGLLSNL

Sequence Length  16

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic (Derived from Alyteserin-2a)

Type  Synthetic peptide

Classification

  

ACP Tumor active peptide



Activity Information


Cell Line Disease Activity Assay Testing Time Literature
A549 Lung adenocarcinoma LC50=35 μM CellTiter-Glo Luminescent Cell Viability assay 24 h 1

Hemolytic Activity  Human erythrocytes: 50% Hemolysis=28 µM

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available



Structure Information


PDB ID  Not available

Predicted Structure  DCTPep02089

(Please note that there is the predicted structure, predicted by AlphaFold)

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C75H137N19O20

Absent amino acids  CDEFHMPQRVWY

Theoretical pI  10.00

Acidic residues  0

Basic residues  2

Polar residues  5

Molecular weight (Average)  1625.03

Molecular weight (Monoisotopic)  1624.03

Common amino acids  L

Net charge  2

Instability index (II)  5.49

Aliphatic index  183.12

Grand average of hydropathicity (GRAVY)  1.081

Half Life 
  20 hours (mammalian reticulocytes, in vitro).
  30 min (yeast, in vivo).
  >10 hours (Escherichia coli, in vivo).

Extinction coefficients 
  Should not be visible by UV spectrophotometry.

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 22965637

Title  Transformation of the naturally occurring frog skin peptide, alyteserin-2a into a potent, non-toxic anti-cancer agent

Doi 10.1007/s00726-012-1395-7

Year  2013

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_4361

DCTPep is developed by Dr.Zheng's team.